News

Find updates on the work of our researchers here, as well as news about recent advances in Alzheimer's science, funding and awareness.

New Alzheimer’s Gene, CD33, May Hold Key to Treatment

BOSTON— Excessive levels of the protein CD33 can impede the clearance of the plaque-forming protein, amyloid beta, the key component of senile plaques in the brains of Alzheimer’s disease patients. The discovery, made by Dr. Rudolph Tanzi and colleagues at Massachusetts General Hospital, and co-funded by the Cure Alzheimer’s Fund and the National Institute of Mental Health (NIMH) will be published in the journal Neuron.

Events at the Marathon in Boston

Cure Alzheimer’s Fund is saddened by the terror attack at the Boston Marathon.  Our hearts go out to all who have been affected by these horrible incidents. We are so proud of the runners, all those behind the scenes and all who supported our marathon running team this year. We are happy to report that none of our team was near enough to the blasts to be injured. We want to say thank you to those who supported our marathon team. Also thanks to the many of you who have expressed concern.

Exposure to Air Pollution May Increase Risk of Alzheimer’s Disease

The study, led by Cure Alzheimer’s Research Consortium member Sam Gandy, M.D., Ph.D., of the Icahn School of Medicine at Mount Sinai, examined how elements in air pollution such as nickel nanoparticles affect the levels of certain peptides in the brain that are found to be at heightened levels in patients suffering from Alzheimer’s Disease.

“We don’t yet completely understand why the peptides accumulate, but we do know the genes responding to the peptides play an important role in developing Alzheimer’s,” said Gandy.

President’s Budget Proposed Increase for Alzheimer’s Disease Research

The President states in the budget message for the National Institutes of Health that the proposed budget delivers on the "...  Administration's commitment to enhance investment in Alzheimer's research" by adding approximately $80 million to the current year’s amount. This commitment which moves Alzheimer’s research from about 1.6% of the NIH budget to about 1.8% includes, "... investments in basic research on the fundamental causes and mechanisms of disease ..."

Traumatic Brain Injury Linked to Alzheimer's and Other Neurodegenerative Diseases

Traumatic Brain Injury (TBI) can lead to neurodegenerative syndromes that include Alzheimer's Disease (AD) and Chronic Traumatic Encephalopathy (CTE).

The April issue of Nature Reviews Neurology is devoted to Traumatic Brain Injury (TBI) and Chronic Traumatic Encephalopathy (CTE). Cure Alzheimer’s Fund research consortium member, Sam Gandy, M.D., Ph.D., of the Icahn School of Medicine at Mount Sinai is senior author of the lead review and overview.

BRAIN Initiative and RAND Study: An Assessment

Over the last several days, two important announcements pertaining to Alzheimer's and other neurological diseases have been made.

Dementia Costs On Par with Cancer and Heart Disease

According to a new RAND study published today in the New England Journal of Medicine, dementia care costs are now comparable to those of heart disease and cancer. And unlike most chronic diseases, rates of dementia in the population are rising rapidly. The study estimates that about 3.8 million Americans currently suffer from dementia, and predicts that this number will climb to 9.1 million by 2040. The cost of the disease to the country will rise proportionally if a cure is not found.

Reprogramming Cells to Understand Alzheimer's Disease

Collaboration with the New York Stem Cell Foundation will involve using skin samples and brain imaging to identify causes and cures

Stem Cells Accelerate Research & Drug Discovery

Washington—Uncovering the cure for Alzheimer’s disease at a rate never before possible and giving individuals a way to better understand their chances of facing Alzheimer’s are the outcomes of new advances in stem cell research from the Cure Alzheimer’s Fund (CAF) Stem Cell Research Consortium that use skin samples to identify potential therapies for the disease.

Senior Vice President Sally Rosenfield Joins Women Against Alzheimer’s Network

WASHINGTON –Joining as the newest member of the Founding Board for the Women Against Alzheimer’s Network is Senior Vice President of Cure Alzheimer’s Fund, Sally Rosenfield.

Bringing together women from across the country who are leading the way in Alzheimer’s research, the Women Against Alzheimer’s Founding Network focuses on “harness[ing] the power of women” to build an “aggressive plan to prevent and treat Alzheimer’s disease.”